

EVALUATION OF AQUEOUS EXTRACT OF
Syzygium polyanthum **LEAVES AS ANTI-**
HYPERTENSIVE AGENT IN SPONTANEOUS
HYPERTENSIVE RAT (SHR)

NURUL SYAHIDA BINTI RAMLI

UNIVERSITI SAINS MALAYSIA

2021

EVALUATION OF AQUEOUS EXTRACT OF
Syzygium polyanthum **LEAVES AS ANTI-**
HYPERTENSIVE AGENT IN SPONTANEOUS
HYPERTENSIVE RAT (SHR)

by

NURUL SYAHIDA BINTI RAMLI

Thesis submitted in fulfillment of the requirements

for the degree of

Doctor of Philosophy

May 2021

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude and appreciation to my supervisor, Dr. Wan Amir Nizam b. Wan Ahmad, who convincingly guided and encouraged me to get things done and making sure that I am on the right track, even when the road got tough. Without his persistent help and continuously motivated me, the objectives of this study would not have been achieved.

Many thanks are also dedicated to all my co-supervisors, Dr. Liza bt. Noordin, Dr. Nor Hidayah bt. Abu Bakar and Dr. Azlini bt. Ismail who willingly took time out of their hectic schedule to guide the young learner like me on what I should do when I am in the dark. Their expertise was really appreciated and inspired me to think outside of the box. I am also forever indebted to all staff from Animal Research and Service Centre (USM Health Campus), Central Research Laboratory (School of Medical Sciences), Scanning Electron Microscope Laboratory (School of Health Sciences) and Biomedicine Laboratory (School of Health Sciences) for giving me the opportunity to work in their laboratories and persistently assist me in many aspects of my studies. Greatest gratitude to my friends and labmates, Asiah, Afifah, Aina, Nadiah, Bibi and Syahidah for their kindness in supporting me over the last three years.

Last but not least, I wish to acknowledge the endless love and support of my beloved husband Shafizol b. Zainuddin, my little son Muhammad Ammar Aydan b. Shafizol, my parents Ramli b. Ahmad and Ibrizi bt. Ibrahim, my parents-in-law Zainuddin b. Mahmud and Zakiah bt. Zakaria, siblings and siblings-in-law. Without them, I would not have survived the challenges of this PhD. This research project was funded by Short Term Grant (304/PPSK/61312059).

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	xi
LIST OF FIGURES	xiii
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS	xxi
ABSTRAK	xxv
ABSTRACT	xxvii
CHAPTER 1 INTRODUCTION	1
1.1 Background of the study	1
1.2 Problem statement	5
1.3 Objectives of the study	5
1.3.1 General objective	5
1.3.2 Specific objectives	6
1.4 Significance of the study	6
CHAPTER 2 LITERATURE REVIEW	8
2.1 Non-communicable disease (NCD)	8
2.2 Hypertension	9
2.2.1 Definition	9
2.2.2 Blood pressure categories	9
2.2.3 Prevalence	11
2.2.3(a) Worldwide	11
2.2.3(b) Malaysia	11

2.2.4	Pathophysiological factors of hypertension development	12
2.3	Oxidative stress in hypertension	14
2.4	Complications and consequences of hypertension	17
2.4.1	Blood vessel.....	18
2.4.1(a)	Normal structure of blood vessel.....	18
2.4.1(b)	Alteration of vascular components.....	22
2.4.2	Renal	24
2.4.2(a)	Normal structure of the kidney.....	24
2.4.2(b)	Renal damage associated with hypertension	28
2.5	Renin-angiotensin-aldosterone system (RAAS).....	30
2.6	Current management of hypertension.....	33
2.6.1	Non-pharmacological.....	33
2.6.2	Pharmacological.....	33
2.6.3	Limitation in current management.....	36
2.7	Ethnomedicinal plants for hypertension	37
2.8	<i>Syzygium polyanthum</i> (Wight) Walp. var. <i>Polyanthum</i>	40
2.8.1	Ethnomedicinal uses of <i>S. polyanthum</i>	43
2.7.2	<i>S. polyanthum</i> used in pharmacological studies	44
2.8.3	Phytochemical profiling and its possible antihypertensive compounds	46
2.8.4	Potential of the ACE inhibitor as antihypertensive agent.....	50
2.8.5	Plant safety and toxicity.....	52
2.9	Animal models in hypertension research.....	53
CHAPTER 3 METHODOLOGY		55

3.1	Materials	55
3.1.1	Chemicals and reagents	55
3.1.2	Commercial kits	58
3.1.3	Laboratory equipment	59
3.2	Experimental design	61
3.3	Plant materials	61
3.3.1	Collection of plant materials	61
3.3.2	Authentication of plant materials	61
3.4	Aqueous extraction of plant materials	64
3.5	Qualitative phytochemical analysis of aqueous extract (AESP)	69
3.5.1	Tests for phenolics (Ferric chloride test)	69
3.5.2	Tests for flavonoids	70
3.5.3	Tests for alkaloids	70
3.5.4	Tests for terpenoids (Salkowski test)	70
3.5.5	Tests for tannins	71
3.5.6	Tests for saponins (frothing test)	71
3.5.7	Tests for steroids	72
3.5.8	Tests for glycosides (Salkowski's Test)	72
3.5.9	Tests for cardiac glycosides (Keller-killiani test)	72
3.5.10	Tests for quinones	73
3.5.11	Tests for resins	73
3.5.12	Tests for anthraquinones	73
3.5.13	Tests for xanthoproteins	74
3.5.14	Tests for coumarins	74
3.6	Phytochemical profiling of aqueous extract (AESP)	75

3.6.1	Gallic acid detection using Thin-Layer Chromatography (TLC)	75
3.6.2	Gallic acid quantification using High-Performance Liquid Chromatography (HPLC)	77
3.7	Quantitative phytochemical analysis of aqueous extract (AESP)	78
3.7.1	Total phenolic contents	78
3.7.2	Total flavonoid contents	81
3.8	Total antioxidant capacity assays in AESP	83
3.8.1	Ferric reducing antioxidant power (FRAP) assay.....	83
3.8.1(a)	Reagents preparation	83
3.8.1(b)	Test principle and protocols	84
3.8.2	DPPH free radical-scavenging assay	86
3.8.2(a)	Reagent preparation.....	86
3.8.2(b)	Test principle and protocols	86
3.9	Measurement of antihypertensive activity: Angiotensin-converting enzyme (ACE) inhibitory (<i>in vitro</i>).....	88
3.9.1	Reagents preparation.....	88
3.9.2	Protocols	89
3.10	<i>In vivo</i> anti-hypertensive activity of AESP	91
3.10.1	Experimental animals	91
3.10.2	Sample size calculation.....	92
3.10.3	Experimental design	93
3.10.4	Animal treatments and dose selection	97
3.10.5	Determination of blood pressure.....	99
3.10.6	Blood collection for biochemical estimation, measurement of oxidative stress markers and Angiotensin-converting enzyme (ACE) level..	103

3.10.7	Samples collection of organs for histology study.....	106
3.10.7(a)	Kidney isolation	106
3.10.7(b)	Descending thoracic aorta isolation	107
3.10.8	Determination of oxidative stress markers	109
3.10.8(a)	Malondialdehyde (MDA).....	109
3.10.8 (a)(i)	Test principle	109
3.10.8 (a)(ii)	Protocols	109
3.10.8(b)	Total Antioxidants Capacity (TAC).....	110
3.10.8(b)(i)	Test principle	110
3.10.8(b)(ii)	Protocols	110
3.10.8(c)	Superoxide dismutase activity (SOD).....	111
3.10.8(c)(i)	Test principle.....	111
3.10.8(c)(ii)	Protocols	112
3.10.8(d)	Catalase (CAT).....	113
3.10.8(d)(i)	Test principle	113
3.10.8(d)(ii)	Protocols	114
3.10.9	Measurement of Angiotensin I-converting enzyme (ACE) level	115
3.10.9(a)	Test principle.....	115
3.10.9(b)	Protocols.....	116
3.10.10	Histology Analysis	116
3.10.10(a)	Hematoxylin and eosin (H&E) staining	117
3.10.10(a)(i)	Fixation	117
3.10.10(a)(ii)	Tissue processing.....	117
3.10.10(a)(iii)	Embedding	118
3.10.10 (a)(iv)	Sectioning	118

3.10.10(a)(vi) Staining	119
3.10.10(a)(iv) Histology assessment	120
3.10.10(b) Scanning electron microscope.....	126
3.11 Statistical analyses	130
CHAPTER 4 RESULTS	131
4.1 Percentage yields (% w/w) of extract from <i>S. polyanthum</i> (AESP) leaves	131
4.2 Qualitative phytochemical screening in AESP.....	131
4.3 Phytochemical profiling analysis in AESP.....	135
4.3.1 Gallic acid detection using Thin-Layer Chromatography (TLC)	135
4.3.2 Gallic acid quantification using High-Performance Liquid Chromatography (HPLC)	135
4.4 Quantitative phytochemical analysis in AESP	139
4.4.1 Total phenolic contents estimation	139
4.4.2 Total flavonoid contents estimation.....	139
4.5 Total antioxidant capacity level in AESP	141
4.5.1 Ferric reducing antioxidant power (FRAP) estimation.....	141
4.5.2 Inhibition of DPPH free radical-scavenging (IC ₅₀) activity	143
4.6 Angiotensin-converting enzyme (ACE) inhibitory (<i>in vitro</i>) activity in AESP	145
4.7 <i>In vivo</i> antihypertensive activity of AESP	145
4.7.1 Effects of AESP on systolic blood pressure	145
4.7.1(a) Baseline systolic blood pressure	145
4.7.1(b) Systolic blood pressure during 12 weeks of treatment.....	147
4.7.2 Effects of AESP on biochemical parameters	149

4.7.2(a)	Effects in renal function test (RFT).....	149
4.7.2(b)	Effects in full blood counts (FBC).....	149
4.7.3	Effects of AESP on relative kidney weight	152
4.7.4	Effects of AESP on the levels of oxidative stress markers in the serum.....	154
4.7.5	Effects of AESP on plasma Angiotensin-converting enzyme (ACE) concentrations	156
4.7.6	Effect of AESP on histology of thoracic aorta	158
4.7.6(a)	Haematoxylin and Eosin (H&E) stain.....	158
4.7.6(b)	Scanning electron microscope.....	167
4.7.7	Effect of AESP on histology of kidney	176
4.7.7(a)	Haematoxylin and Eosin (H&E) stain.....	176
4.7.7(b)	Scanning Electron Microscope.....	184
CHAPTER 5 DISCUSSION.....		191
5.1	Yields of AESP.....	191
5.2	Qualitative phytochemical screening in AESP.....	192
5.3	Phytochemical profiling analysis in AESP.....	194
5.4	Quantitative phytochemical screening in AESP.....	195
5.5	Total antioxidant capacity level in AESP.....	197
5.6	Angiotensin-converting enzyme (ACE) inhibitory (<i>in vitro</i>) activity in AESP	200
5.7	<i>In vivo</i> antihypertensive activity of AESP.....	201
5.7.1	Effects of AESP on systolic blood pressure	201
5.7.2	Effects of AESP on biochemical parameters	204

5.7.3	Effects of AESP on relative kidney weight	207
5.7.4	Effects of AESP on serum oxidative stress markers.....	208
5.7.5	Effects of AESP on plasma Angiotensin-converting enzyme (ACE) concentration.....	211
5.7.6	Effects of AESP on thoracic aorta histology	213
5.7.7	Effects of AESP on kidney histology	216
CHAPTER 6 CONCLUSION & FUTURE RECOMMENDATIONS		221
6.1	Conclusion	221
6.2	Future Recommendations	223
REFERENCES.....		224
APPENDIX A: PLANT AUTHENTICATION		
APPENDIX B: PREPARATION OF DRAGONDORFF” REAGENT		
APPENDIX C: ANIMAL ETHICAL APPROVAL		
APPENDIX D: CALCULATION FOR 3 DIFFERENT DOSAGES OF AESP PREPARATION		
APPENDIX E: CALCULATION FOR LOSARTAN		
APPENDIX F: CALCULATION FOR SODIUM PENTOBARBITAL SOLUTION (6%) PREPARATION		
APPENDIX G: LIST OF PUBLICATIONS AND PRESENTATIONS		

LIST OF TABLES

	Page
Table 2.1	Blood Pressure Categories 10
Table 2.2	Pathophysiological factors that are causing hypertension..... 13
Table 2.3	End organ damage in arterial hypertension. 17
Table 2.4	Local ethnomedicinal plants with proven scientific findings related to the potential of treating hypertension 38
Table 2.5	Scientific findings of <i>S. polyanthum</i> 45
Table 2.6	Total phenolics and total flavonoids contents in the extracts of <i>S.</i> <i>polyanthum</i> 47
Table 3.1	List of chemicals and reagents 55
Table 3.2	List of commercial kits 58
Table 3.3	List of laboratory equipment..... 59
Table 3.4	Batches of sample collections 63
Table 3.5	Gradient elution system used in HPLC..... 78
Table 3.6	Reagent preparation in FRAP assay 84
Table 3.7	Reagent preparation in DPPH assay 86
Table 3.8	Reagent preparation in ACE inhibitory assay..... 88
Table 3.9	List of treatments given and their dosage and dilution. 98

Table 3.10	Tissue processing protocol.....	120
Table 3.11	Protocol guidelines for tissue processing in the Scanning electron microscope (SEM) provided by SEM Laboratory, PPSK, USM, Kelantan.....	129
Table 4.1	Yields of AESP	132
Table 4.2	Phytochemical groups present in <i>S. polyanthum</i> leaves extracts ...	134
Table 4.3	Quantity of gallic acid in AESP	138
Table 4.4	Mean DPPH radical scavenging activity at 50 µg/mL of extract. .	144
Table 4.5	The effects of AESP on renal parameters.....	148
Table 4.6	Full blood count parameters after 12 th weeks of AESP supplementation.....	151
Table 4.7	The effects of AESP on oxidative stress markers	155

LIST OF FIGURES

	Page
Figure 2.1	Oxidative stress is a key factor that leads to hypertension 15
Figure 2.2	Blood vessel layers. 19
Figure 2.3	Functions of endothelial cells..... 19
Figure 2.4	The blood vessel underwent vascular remodeling in response to increased resistance to blood flow. 23
Figure 2.5	Internal regions of the kidney and its functional unit (nephron). .. 26
Figure 2.6	Close-up of the barrier layers in the glomerulus capillary wall, the podocytes and the filtration slits. 27
Figure 2.7	Renin-angiotensin-aldosterone system (RAAS) pathway..... 32
Figure 2.8	Angiotensin II Blocker Receptor Mechanism (ARBs). 35
Figure 2.9	<i>Syzygium polyanthum</i> (Wight) Walp. var. <i>Polyanthum</i> . A) Tree, B) Leaves, C) Flowers, D) Unripe fruits, and E) Ripe fruit 42
Figure 3.1	Overall study design 62
Figure 3.2	The leaves were washed and cleaned with tap water. 66
Figure 3.3	The cleaned leaves were dried in the incubator at 50°C..... 66
Figure 3.4	<i>S. polyanthum</i> leaves that had been dried. 66
Figure 3.5	The dried leaves were ground into powder using laboratory grinder..... 67
Figure 3.6	AESP was prepared using ultrasound-assisted extraction technique (UAE.)..... 67

Figure 3.7	The powders were being sonicated.....	67
Figure 3.8	The extract was double-filtered using filter paper.....	68
Figure 3.9	The overnight frozen extract was freeze-dried using freeze dryer	68
Figure 3.10	Aqueous extract of <i>Syzygium polyanthum</i> (AESP) powder was obtained.....	68
Figure 3.11	Basic structure of flavonoid.....	81
Figure 3.12	Formula of R_f value.....	76
Figure 3.13	Routine oral gavage for 12 weeks	94
Figure 3.14	Rat's restrainer set (Model 81 IITC)	95
Figure 3.15	Rats were able to move freely in the restrainer tube; without capping the nose and tail during acclimatisation period.....	95
Figure 3.16	<i>In vivo</i> Study Design.....	96
Figure 3.17	Tail-cuff blood pressure instrument, IITC.....	101
Figure 3.18	Rat was set up in a restrainer, ready for blood pressure measurement.	101
Figure 3.19	Tail cuff equipped with photosensor	102
Figure 3.20	Real tracing of systolic blood pressure (SBP).....	102
Figure 3.21	The rat was euthanised using Sodium pentobarbitone (100 mg/kg) via intraperitoneal injection.....	104
Figure 3.22	The blood was withdrawn via cardiac puncture technique.....	104

Figure 3.23	Isolation of kidney.....	107
Figure 3.24	Isolation of descending thoracic aorta.....	108
Figure 3.25	Activity of superoxide dismutase.....	112
Figure 3.26	Degradation of catalase.....	113
Figure 3.27	Tissue processing was done using Automated Tissue Processor....	121
Figure 3.28	Tissue embedding process using Paraffin dispenser.....	121
Figure 3.29	Paraffin blocks after the embedding process.....	121
Figure 3.30	Blocked tissue of interest after embedding process.....	122
Figure 3.31	Sectioning of tissue block using Microtome.....	122
Figure 3.32	Floating out the ideal ribbon on the water surface of tissue floatation bath.....	122
Figure 3.33	Picking up section from tissue floatation bath.....	123
Figure 3.34	Drying slides in the upright position to allow quick drying.....	123
Figure 3.35	Fixing the tissue slide using Slide warmer.....	123
Figure 3.36	Slides were stained with Hematoxylin and Eosin staining.....	124
Figure 3.37	Mounting the section onto the microscope slide using DPX.....	124
Figure 3.38	Protocol of hematoxylin & eosin (H&E) stain.....	125
Figure 3.39	Process of tissue dehydration.....	127
Figure 3.40	Samples were dried using Critical point dryer.....	127

Figure 3.41	Samples were arranged onto the stand holder to be coated with gold and platinum using Sputter coater.....	128
Figure 3.42	Samples were placed on the stand holder and viewed under Scanning electron microscope.....	128
Figure 4.1	The observed colour changes when AESP was subjected to various phytochemical screening tests.....	133
Figure 4.2	The standard calibration curve of gallic acid in the total phenolic assay.....	140
Figure 4.3	The standard calibration curve of quercetin in the total flavonoid assay.....	140
Figure 4.4	TLC profiling images of AESP and standard gallic acid when viewed under UV lamp.....	136
Figure 4.5	HPLC chromatogram of AESP at wavelength of 280 nm with standard reference gallic acid.	137
Figure 4.6	Gallic acid standard curve..	138
Figure 4.7	FeSO ₄ standard curve.	142
Figure 4.8	Mean Ferric reducing antioxidant capacity of extract.....	142
Figure 4.9	Mean DPPH radical scavenging activity (%) versus concentration (µg/mL).....	144
Figure 4.10	Mean ACE inhibition by AESP in comparison to captopril.....	146

Figure 4.11	Baseline measurement of systolic blood pressure between WKY and SHR.....	146
Figure 4.12	Mean effect of AESP on systolic blood pressure in experimental groups during the treatment period of 12 weeks.....	148
Figure 4.13	Effect of AESP on percentage relative kidney weight of right kidney SHR after the treatment period of 12 weeks.....	153
Figure 4.14	Effect of AESP on percentage relative kidney weight of left kidney SHR after the treatment period of 12 weeks.....	153
Figure 4.15	Effect of AESP on plasma levels of angiotensin-converting enzyme (ACE) after the treatment period of 12 weeks in experimental groups.....	157
Figure 4.16	The mean thickness of tunica media in experimental groups.....	160
Figure 4.17(a)	Thoracic aorta of normal WKY rat (under 4x and 20x magnifications).....	161
Figure 4.17(b)	Thoracic aorta of normal WKY rat (under 4x magnification).....	161
Figure 4.18(a)	Thoracic aorta of untreated-SHR rat (under 4x and 20x magnifications).....	162
Figure 4.18(b)	Thoracic aorta of untreated-SHR rat (under 40x magnification).....	162

Figure 4.19(a)	Thoracic aorta of Losartan-treated rat (under 4x and 20x magnifications).	163
Figure 4.19(b)	Thoracic aorta of Losartan-treated rat (under 40x magnifications).	163
Figure 4.20(a)	Thoracic aorta of 1500mg/kg AESP-treated rat (under 4x and 20x magnifications).	164
Figure 4.20(b)	Thoracic aorta of 1500mg/kg AESP-treated rat (under 40x magnification).	164
Figure 4.21(a)	Thoracic aorta of 1750mg/kg AESP-treated rat (under 4x and 20x magnifications).	165
Figure 4.21(b)	Thoracic aorta of 1750mg/kg AESP-treated rat (under 40x magnification).	165
Figure 4.22(a)	Thoracic aorta of 2250mg/kg AESP-treated rat (under 4x and 20x magnifications).	166
Figure 4.22(b)	Thoracic aorta of 2250mg/kg AESP-treated rat (under 40x magnification).	166
Figure 4.23	Scanning electron microscopic images showing normal WKY thoracic aorta (a-b) (under 130x and 1000x; respectively).	169
Figure 4.24	Scanning electron microscopic images showing untreated-SHR thoracic aorta (a-b) (under 130x and 1000x; respectively).	170
Figure 4.24	Scanning electron microscopic images showing untreated-SHR thoracic aorta (c) (under 3000x).	171
Figure 4.25	Scanning electron microscopic images showing Losartan-treated SHR thoracic aorta (a-b) (under 130x and 1000x; respectively). ..	172

Figure 4.26	Scanning electron microscopic images showing 1500mg/kg AESP-treated SHR thoracic aorta (a-b) (under 130x and 1000x; respectively).....	173
Figure 4.27	Scanning electron microscopic images showing 1750mg/kg AESP-treated SHR thoracic aorta (a-b) (under 130x and 1000x; respectively).....	174
Figure 4.28	Scanning electron microscopic images showing 2250mg/kg AESP-treated SHR thoracic aorta (a-b) (under 130x and 1000x; respectively).....	175
Figure 4.29	Normal kidney of WKY rat (a-c) (under 10x, 20x and 40x magnifications).	178
Figure 4.30	Damaged kidney of untreated-SHR (a-c) (under 10x, 20x and 40x magnifications).	179
Figure 4.31	Renal corpuscle in the Losartan-treated SHR (a-c) (under 10x, 20x and 40x magnifications).	180
Figure 4.32	Renal corpuscle in the 1500mg/kg AESP-treated SHR (a-c) (under 10x, 20x and 40x magnifications).	181
Figure 4.33	Renal corpuscle in the 1750mg/kg AESP-treated SHR (a-c) (under 10x, 20x and 40x magnifications).	182
Figure 4.34	Renal corpuscle in the 2250mg/kg AESP-treated SHR (a-c) (under 10x, 20x and 40x magnifications).	183
Figure 4.35	Scanning electron microscopic images showing normal WKY kidney (a-b) (under 2500x and 10,000x; respectively).....	185
Figure 4.36	Scanning electron microscopic images showing untreated-SHR kidney (c-d) (under 2500x and 10,000x; respectively).....	186

Figure 4.37	Scanning electron microscopic images showing the effects of Losartan-treatment on rat's kidney. (e-f) (under 2500x and 10,000x respectively).....	187
Figure 4.38	Scanning electron microscopic images showing the effects of 1500mg/kg AESP-treatment on rat's kidney. (g-h) (under 2500x and 10,000x respectively).....	188
Figure 4.39	Scanning electron microscopic images showing the effects of 1750mg/kg AESP -treatment on rat's kidney. (i-j) (under 2500x and 10,000x respectively).....	189
Figure 4.40	Scanning electron microscopic images showing the effects of 2250mg/kg AESP-treated on rat's kidney. (k-l) (under 2500x and 10,000x; respectively).....	190
Figure 5.1	Schematic diagram on the pathogenesis of hypertension by AESP.....	220

LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS

ACE	angiotensin-converting enzyme
ACEI/s	angiotensin-converting enzyme inhibitor/s
AESP	aqueous extract from <i>S. polyanthum</i>
Ang II	angiotensin II
Animal (K_m)	constant used for the animal
ANOVA	analysis of variance
ARASC	Animal Research and Service Centre
ARBs	angiotensin receptor blockers
BBs	beta blockers
BHT	butylated hydroxytoluene
BP	blood pressure
BSA	body surface area
C	concentration of gallic acid from the calibration curve
c	concentration of quercetin from the calibration curve
CAE	caffeic acid equivalent
CAT	catalase
CCBs	calcium channel blockers
CE	catechin equivalent
CVD	cardiovascular disease
DBP	diastolic blood pressure
DPPH	2,2-Diphenyl-1-Picrylhydrazyl
DPX	distyrene plasticizer xylene
EA	ethyl acetate
ECM	extracellular matrix
EDTA	ethylenediaminetetraacetic acid
FBC	full blood counts
FE	flavonol equivalent

FRAP	ferric reducing antioxidant power
FRIM	Forest Research Institute Malaysia
GA	gallic acid
GAE	gallic acid equivalent
GCMS	gas chromatography and mass spectrometry
GP _x	glutathione peroxidase
HA	hippuric acid
HCL	hydrochloride acid
4-HNE	4-hydroxynonenal
H.E.D.	human equivalent dose
H ₂ O ₂	hydrogen peroxide
HHL	Hippuryl-Histidyl-Leucine
H&E	hematoxylin and eosin
HPLC	high-performance liquid chromatography
HRP	horseradish peroxidase
Human (K _m)	constant for human
IC ₅₀	half inhibitory concentration
IMR	Institute for Medical Research
IP	intraperitoneal .
LC-MS	liquid chromatography-mass spectrometry
M	mass of dry extract
MDA	malondialdehydes
Meth	methanol
mg GAE/1g	mg gallic acid equivalents per 1g of plant material
mM FE /1 mg	mM Ferrous equivalents per 1mg of the dry extract
mg QE/1g	mg quercetin equivalents per 1g of plant material
NaCl	sodium chloride
NCD	non-communicable disease
NHMS	National Health and Morbidity Surveys
NOS	nitric oxide synthase

O ₂ ^{•-}	superoxide anion radical
OD	optical density
OH	hydroxyl radical
QE	quercetin equivalent
RAAS	renin –angiotensin –aldosterone system
RE	rutin equivalent
R _f values	retention factor
ROS	reactive oxygen species
R ²	regression coefficient
<i>S. polyanthum</i>	<i>Syzygium polyanthum</i>
SBP	systolic blood pressure
S.D.	standard deviation
SEM	scanning electron microscope
S.E.M.	standard error of the means
SGPT/ ALT	serum glutamic pyruvic transaminase/ Alanine transaminase
SHR	spontaneously hypertensive rats
SOD	superoxide dismutase
T&CM	traditional and complementary medicine
TAC	total antioxidant capacity
TBA	thiobarbituric acid
TFC	total flavonoid content
TLC	thin-layer chromatography
TPC	total phenolic content
TPTZ	2,4,6-Tris (2-pyridyl)-s-triazine
UAE	ultrasound-assisted extraction
UV	ultraviolet
UV-Vis	ultraviolet-visible
V	volume of the extract

VSMC	vascular smooth muscle cell
WHO	World Health Organization
WKY	wistar Kyoto
X	distance of solvent front travelled from its origin
XO	xanthine oxidase
Y	distance of spot travelled from its origin
α	type 1 error probability
β	power of study
δ	the difference in means for selected parameter
σ	within group standard deviation
m	ratio of control to experimental group
ppm	parts per million

**PENILAIAN EKSTRAK AKUEUS DAUN *Syzygium polyanthum* SEBAGAI
AGEN ANTI-HIPERTENSI DALAM TIKUS BERHIPERTENSI SPONTAN**

(SHR)

ABSTRAK

Hipertensi berkait dengan morbiditi dan mortaliti yang ketara. Penggunaan herba perubatan sebagai perubatan alternatif untuk menguruskan hipertensi meningkat secara exponen. *Syzygium polyanthum* (*S. polyanthum*), telah diakui sebagai agen antihipertensi secara tradisional. Kajian ini bertujuan untuk mengenalpasti kesan antihipertensi daripada ekstrak akueus daun *S. polyanthum* (AESP) dan mekanisme dengan menggunakan tikus berhipertensi spontan (SHR). Profil fitokimia, pelbagai ciri antioksidan dan aktiviti antihipertensi telah dinilai. Lima puluh ekor SHR jantan telah dibahagikan sama rata kepada 5 kumpulan: SHR tidak-terawat, Losartan-terawat, 3 kumpulan dos AESP-terawat yang berbeza (1500 mg/kg, 1750 mg/kg dan 2250 mg/kg) dan 10 WKY jantan sebagai kawalan. Semua rawatan diberi secara oral selama 12 minggu. Tekanan darah sistolik (SBP) diukur setiap 2 minggu. Analisa biokimia, penanda tekanan oksidatif, dan tahap enzim *Angiotensin-converting* (ACE) telah dinilai pada penghujung kajian. Histologi aorta toraks dan ginjal telah dinilai menggunakan pewarnaan hematoksilin & eosin (H&E), dan mikroskop imbasan elektron (SEM). AESP mengandungi flavonoid dan fenol, dengan asid galik telah dikenalpasti. AESP menunjukkan aktiviti antioksidan dan perencat-ACE *in vitro* tinggi. Dalam SHR AESP-terawat; SBP menurun secara ketara, fungsi ginjal dan penanda tekanan oksidatif ditambahbaik. Walau bagaimanapun, hanya AESP (2250 mg/kg) menurunkan kepekatan ACE secara ketara. Terdapat juga penambahbaikan histologi aorta toraks dan ginjal dalam SHR AESP-terawat. Oleh itu, kajian

mencadangkan pelbagai ciri antihipertensi AESP disebabkan oleh antioksidannya (terutamanya asid galik) dan aktiviti perencat ACE. Kajian juga mencadangkan mekanisma antihipertensi *S. polyanthum* melakukan aktiviti perencatan melalui perencatan tindakan ACE yang mungkin melibatkan laluan RAAS.

**EVALUATION OF AQUEOUS EXTRACT OF *Syzygium polyanthum* LEAVES
AS ANTI-HYPERTENSIVE AGENT IN SPONTANEOUS HYPERTENSIVE
RAT (SHR)**

ABSTRACT

Hypertension is associated with significant morbidity and mortality. The use of medicinal herbs as alternative medicines to manage hypertension is increasing exponentially. *Syzygium polyanthum*, has been claimed traditionally as an antihypertensive agent. This study aimed to determine the antihypertensive effects of the aqueous extract of *S. polyanthum* (AESP) leaves and its mechanisms using spontaneously hypertensive rats (SHR). The phytochemical profiling, antioxidant properties and antihypertensive activity were evaluated. Fifty male SHR were divided equally into 5 groups; untreated-SHR, Losartan-treated, 3 groups of AESP-treated with different dosages (1500 mg/kg, 1750 mg/kg and 2250 mg/kg), and 10 male WKY rats as control. All treatments were given orally for 12th weeks. Systolic blood pressure (SBP) was measured biweekly. Whereas, the biochemical analysis, oxidative stress markers and angiotensin-converting enzyme (ACE) level were evaluated at the end of the study. The histology of thoracic aorta and kidney were assessed using haematoxylin & eosin (H&E) staining, and scanning electron microscope (SEM). AESP contains flavonoids and phenols with gallic acid detected. AESP showed high *in vitro* antioxidant and ACE-inhibitory activities. In AESP-treated SHR; SBP reduced significantly, improved renal function and oxidative stress markers. However, only AESP (2250 mg/kg) significantly reduced ACE concentration. There was also histology improvement of the thoracic aorta and renal in AESP-treated SHR. Hence, the study suggests that antihypertensive properties of AESP are due to its antioxidant

(mainly gallic acid) and ACE inhibitory activity. Thus, this study reveals the antihypertensive mechanism of AESP exerted inhibitory activity through suppression of the ACE action which might involved RAAS pathway.

CHAPTER 1 INTRODUCTION

1.1 Background of the study

Natural products have been widely used as the primary materials and have played a crucial role in the development of a new drug as a lead compound. The use of medicinal herbs as alternative medicines to manage hypertension is increasing exponentially. The exponential is due to the conservative claim that these products are safe and free from side effects as used in ancient traditional Chinese, Greek-Unani and Ayurvedic medicines (Pandey *et al.*, 2013).

According to the World Health Organization (WHO, 2013a), around 80% of the total world population still relies on herbal products as primary health care. National Health and Morbidity Survey (NHMS) 2015 reported that 0.3% of hypertensive patients chose traditional and complementary medicine (T&CM) as their primary method of treatment (Institute for Public Health, 2015a). Another NHMS 2015 report (Volume IV) on T&CM showed that 40.4% of Malaysian respondents had chosen T&CM as their primary treatment prior to seeking conventional treatment (Institute for Public Health, 2015b). Eighteen point three percent (18.3%) used T&CM practices solely as alternative treatment without seeking conventional treatment.

Many antihypertensive drugs are used to control hypertension, ranging from diuretics, renin inhibitors, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers, calcium channel blockers, α -adrenergic blockers, β -adrenergic blockers to vasodilators. Due to the undesirable side effect of several synthetic drugs

and higher cost of antihypertensive drugs (Kiryama *et al.*, 2016), more experiments have now been concentrated on herbs and medicinal plants as potential hypertensive medicines. The trend was due to reports that medicinal plants contain thousands of bioactive compounds with therapeutic applications (Pan *et al.*, 2013); i.e. phenolics, flavonoids, diterpenoids, and anthocyanins were thought to contribute to cardiovascular and hypertensive pharmacological potential (Fraga *et al.*, 2019). Hence, people are more aware nowadays in seeking natural-based product approaches to replace the role of synthetic products for their treatment of hypertension and other diseases.

Malaysia, a tropical country in Southeast Asia, has a rich diversity of flora and fauna, mostly herbs and medicinal plants. Malay people especially like to eat raw herbs in their daily diet as a condiment (ulam). Malaysia has more than 120 traditional ulam species available, ranging from shrubs to large trees (Abdul Raji *et al.*, 2017). *Syzygium polyanthum* (Wight) Walp or locally known as 'Serai kayu' is one of the favourite ulam that has been consumed for ages. The plant is commonly grown at home and can be found abundantly on the local market. In addition to eating as ulam, the plant's leaves are usually added to "nasi kerabu" and "Kelantanese laksam" among Malay people. Besides, the plant has traditionally been used to treat various diseases such as hypertension, diabetes mellitus, diarrhoea, gastritis, skin diseases and hypercholesterolemia (Sumono and Wulan, 2008). The plant also has multi-biological properties such as antioxidant (Kusuma *et al.*, 2011), antihypertensive (Ismail *et al.*, 2018), antihyperglycaemic (Widyawati *et al.*, 2015a), and antimicrobial properties (Hamad *et al.*, 2017).

Although it is reported that the plant is useful for treating hypertension and other diseases, there is still limited scientific evidence of its antihypertensive activity. Therefore, it is worth scientifically determining the potential benefits of oral administration of this plant in the management of hypertension and its complications. Consideration is needed because the plant's young shoot has been claimed as a supplement to lower the blood pressure (decoction) among hypertensive people for many years.

Later studies by Dafriani (2016) and Aris (2019) confirmed that the water decoction from *S. polyanthum* leaves in hypertensive patients, were able to reduce the blood pressure. In addition, recent animal studies (*in vivo*) have also been successful in demonstrating a further reduction in systolic blood pressure (SBP) over a short-term period of six weeks (Ahmad *et al.*, 2017; Ismail *et al.*, 2018). Even though both studies have confirmed *S. polyanthum* leaves have been able to lower blood pressure (Ahmad *et al.*, 2017; Ismail *et al.*, 2018), the mechanism for the lowering blood pressure is still not clear to date, and none of the long-term studies to confirm this finding have been conducted. This long-term study period (12 weeks of oral administration-*in vivo*) was therefore conducted to reconfirm the anti-hypertensive effect contributed by *S. polyanthum* leaves extract from low to high doses (1500 mg/kg, 1750 mg/kg and 2250 mg/kg) as well as its possible anti-hypertensive grounds for determination.

The reduction of blood pressure could be due to the high presence of antioxidant compounds (particularly gallic acid), a group of phenolic compounds in the leaves (Ismail *et al.*, 2018). There is considerable evidence supporting the view that dietary intake of antioxidants and polyphenols may have an effect in preventing or reducing

hypertension (Baradaran *et al.*, 2014), which further support the leaves are capable of lowering blood pressure. Some studies have also argued that the presence of angiotensin-converting enzyme inhibitor (ACEI) in the plant (Muthia *et al.*, 2017; Ismail and Ahmad, 2019) may also be one of the potential reasons for reducing blood pressure. Yet less is known about *S. polyanthum* leaves' effect on the Renin Angiotensin Aldosterone System (RAAS) and blood pressure pathways. In order to confirm the possible bioactive compounds and the exact pathway responsible for this antihypertensive activity, an extensive study must be carried out.

Because hypertension is associated with damage to target organs (especially blood vessels and kidneys) (Rahimmanesh *et al.*, 2012; Renna *et al.*, 2013), biochemical study, histological studies and oxidative stress activity were also essential to assess in hypertensive research (Siti *et al.*, 2015; Allison, 2016; Ramli *et al.*, 2017, Ramli *et al.*, 2018). In this current study, these three parameters would be done to assess the hypertensive progression and health-enhancing effects of supplying plant extracts.

1.2 Problem statement

Hypertension is one of the major public health problems due to its rapid increase and high prevalence worldwide. The disease can lead to numerous complications, such as heart disease, stroke and kidney failure, which increase the risk of death if not treated early. Although various antihypertensive drugs have been used to control hypertension, there is still insufficient absolute control of hypertension in Malaysia to date. In addition, these medications have been known to cause some detrimental side effects such as depression, delirium, sexual dysfunction, insomnia, and foetal anomalies, which influence people seeking natural plant-based antihypertensive agents (herbs); which are believed to have a wealth of antioxidants to combat cardiovascular risk and its complications. More scientific research is therefore needed to verify the efficacy and to clarify the safety profile of these herbal medicinal products for their antihypertensive potential.

1.3 Objectives of the study

1.3.1 General objective

To evaluate the therapeutic effects of aqueous extract of *S. polyanthum* (AESP) leaves as antihypertensive in the hypertensive rat model.

1.3.2 Specific objectives

1. To determine the phytochemical compounds present in AESP.
2. To determine the *in vitro* antioxidant properties and angiotensin-converting enzyme (ACE) activity in AESP
3. To determine the effects of daily oral administration of AESP for 12 weeks on blood pressure in hypertensive rats.
4. To determine the effects of daily oral administration of AESP for 12 weeks on biochemical parameters (renal function test, full blood count) and angiotensin-converting enzyme level in hypertensive rats after 12 weeks.
5. To determine the effects of daily oral administration of AESP for 12 weeks on histopathology of kidney and descending thoracic aorta in hypertensive rats after 12 weeks.
6. To determine the effects of daily oral administration of AESP for 12 weeks on oxidative stress markers serum levels in hypertensive rats after 12 weeks.

1.4 Significance of the study

The present study provides a fundamental basis for further exploring the possible mechanism of action of the compound (especially gallic acid) found in *S. polyanthum* leaves as an antihypertensive agent with additional benefits for the improvement of the damaged target organ (kidney and blood vessel). This distinctive initiative should promote the use of an agricultural product of *S. polyanthum* as an innovative, practical food product that will help the health of the global community as more citizens become

more aware of their wellness. It will also reduce the country's dependence on imported vegetation and fruit while helping to improve the socio-economic status of local farmers in our country. In addition, citizens will also benefit from various health benefit from a number of pharma-nutritional medicinal products obtained from *S. polyanthum*, and part thereof. This diversification will enhance people's quality of life in line with the Malaysia's New Economic Model national government agenda; deliver a high impact model and sustainability.

CHAPTER 2 LITERATURE REVIEW

2.1 Non-communicable disease (NCD)

Non-communicable disease (NCD), also known as chronic diseases, can be life-threatening and lead to mortality if adequate treatment is not provided. NCD is non-infectious and cannot be transmitted between individuals, and is the result of a combination of genetic, environmental, physiological, and behavioural factors (WHO, 2018).

The four main categories of NCDs are cardiovascular disease (CVD), cancer, chronic respiratory diseases, and diabetes. According to the World Health Organisation (2018), NCD is reported to have killed approximately 41 million people worldwide per year, equivalent to 71% of total deaths, with the largest contributor being CVD. Deaths due to CVD are estimated at 17.9 million people each year, and more than half were due to hypertension, followed by cancers (9.0 million), respiratory diseases (3.9 million) and diabetes (1.6 million) (WHO, 2018).

In Malaysia, NCD caused 73% of the total deaths in Malaysia (NHMS, 2015). The Second Burden of Disease Study for Malaysia, published by the Institute for Public Health (2012), ranked hypertension, high cholesterol, diabetes, high body mass index (BMI), and smoking among the major contributors to CVD and death. Hypertension is also known to be one of the metabolic risk factors associated with NCD that caused premature death worldwide (WHO, 2018).

2.2 Hypertension

2.2.1 Definition

Hypertension, also known as elevated blood pressure (BP), is commonly associated with increased cardiovascular disease. It is often referred to as a 'silent killer' because the symptoms are not too noticeable (Sheih *et al.*, 2009). This is because hypertension can develop into more severe complications that are insidiously undetected. Based on the WHO report (2013b), the risk of death often increases when these complications are left untreated.

Hypertension can be classified as primary hypertension and secondary hypertension. Primary hypertension can be defined as high BP with no known underlying condition. It accounts for 95% of all cases of hypertension. Primary hypertension is a heterogeneous disorder in which different patients have different causal factors leading to high BP (Carretero and Oparil, 2000). Secondary hypertension, on the other hand, can be defined as high BP with known aetiology, including renal parenchymal hypertension, primary aldosteronism, renovascular hypertension, and sleep apnea syndrome. Secondary hypertension was reported to account for 10% of hypertensive patients (Puar *et al.*, 2016).

2.2.2 Blood pressure categories

Normal individuals have systolic blood pressure (SBP) of less than 120 mmHg and

a diastolic blood pressure (DBP) of less than 80 mmHg, i.e. 120/80 mmHg (Unger *et al.*, 2020) (Table 2.1). A further increase of SBP between 120 and 129 mmHg is classified under "Elevated Blood Pressure." Whereas SBP falls between 130 and 139 mmHg, and DBP falls between 80 and 89 mmHg, it is considered to be "Hypertension Stage I." In "Hypertension Stage II" the SBP is more than 140 mmHg, and the DBP is higher than 90 mmHg. If blood pressure continues to rise above 180 mmHg for SBP and above 120 mmHg for DBP, the situation is referred to as "Hypertensive Crisis;" where emergency treatment is needed.

Table 2.1: Blood Pressure Categories. (Unger *et al.*, 2020).

Blood Pressure Category	Systolic mmHg (upper number)		Diastolic mmHg (lower number)
Normal	Less Than 120	and	Less Than 80
Elevated	120-129	and	Less Than 80
High Blood Pressure (Hypertension) Stage 1	130-139	or	80-89
High Blood Pressure (Hypertension) Stage 2	140 or Higher	or	90 or Higher
Hypertensive Crisis (consult your doctor immediately)	Higher Than 180	and/ or	Higher Than 120

2.2.3 Prevalence

2.2.3(a) Worldwide

Every year, the incidence of people with hypertension is rising rapidly worldwide. Currently, 1.13 billion people worldwide are living with hypertension (WHO, 2019). The overall prevalence was estimated at around 30% (NHMS, 2019). In the year 2015, one in four men and one in five women had hypertension, and it is expected that the number of people with hypertension will continue to rise to 1.56 billion by 2025 (Tabrizi *et al.*, 2016). Of the most worrying, hypertension is also reported to cause a total of 7.5 million deaths per year (WHO, 2019). Annual mortality is predicted at 23.5 million people by 2030 (WHO, 2013).

2.2.3(b) Malaysia

The 2015 National Health and Morbidity Survey (NHMS) reported about 6.1 million people or about one in three adults with hypertension in Malaysia. Based on the available reports, the prevalence of hypertension differs between countries, countries and subgroups of a country's populations (Picon *et al.*, 2012). The prevalence was higher in our neighbouring countries, Thailand (23.6%) and Singapore (16%). Based on NHMS 2015, 30.8% of males and 29.7% of females were affected by hypertension. There was also a generally increasing prevalence trend by age, from 6.7% in the 18-19 age group to a peak of 75.4% in the 70-74 age group. The prevalence started to plateau from 2011 (32.6%) to 2015 (30.3%) (NHMS, 2019). For the main ethnic groups, Sabah & Sarawak Bumiputera has the highest prevalence at 36.4%, followed

by Malays at 34.0%, Chinese at 32.3% and Indians at 30.6% (IPH, 2011). Among these, Kelantan, along with Kedah, ranked the highest prevalence at 23.2% of undiagnosed hypertension. The prevalence remained high, as there is still no significant improvement made by the community despite policies and task forces implemented by the government of Malaysia (IPH, 2011; MOH, 2014).

2.2.4 Pathophysiological factors of hypertension development

Numerous pathophysiological factors have been involved in the development of hypertension. Factors include neurohormonal factors, dietary factors, vascular factors, cellular mechanisms, oxidative stress, and other factors (Schulz *et al.*, 2011; Acelajado *et al.*, 2012). Numerous evidence has shown that oxidative stress is the predominant factor that leads to an increase in blood pressure (Ceriello, 2008; Rodrigo *et al.*, 2011; Tsiropoulou *et al.*, 2016). Details of pathophysiological factors that may contribute to hypertension are provided in Table 2.2.

Table 2.2: Pathophysiological factors contribute to hypertension. (Schulz *et al.*, 2011; Acelajado *et al.*, 2012).

Pathophysiologic Factor	Mechanism (Increased or decreased activity)
Neurohormonal Mechanism SNS activity RAAS Production of sodium retaining hormones Production and expression of vasoconstrictors Production and expression of vasodilators Kallikrein-kinin system activity	Increased Increased Increased Increased Decreased Decreased
Dietary Factors Sodium intake Potassium and calcium intake	Increased Decreased
Vascular Factors Peripheral resistance Vascular stiffness Endothelial dysfunction	Increased Increased Increased
Cellular Mechanisms Cellular ion transport Adrenergic receptor activity	Increased or decreased Increased or decreased
Others Inflammation Psychosocial stress Oxidative stress Genetic Environment	Increased Increased Increased Increased Increased

2.3 Oxidative stress in hypertension

Oxidative stress is generally known to cause many types of disease. One of these is the key factors that make progress towards hypertension (Rodrigo *et al.*, 2011; Montezano and Touyz, 2012) (Figure 2.1). This occurs when an imbalance exists between the production of reactive oxygen species (ROS) and the antioxidant defence system. In normal physiological conditions, ROS plays an important role in the maintenance of vascular function and its structure. However, under pathophysiological conditions (due to radical exposure, ageing, etc.), ROS overproduction will promote endothelial dysfunction, vascular remodeling and inflammation, ultimately leading to vascular damage and other complications, including kidney damage (Ozbek, 2012; Dikalov and Nazarewicz, 2013; Tsiropoulou *et al.*, 2016).

There are several types of ROS that can be detected within the vessel, including superoxide anion radical ($O_2^{\cdot-}$), hydroxyl radical ($\cdot OH$), singlet oxygen, hypochlorite radicals, nitric oxide radicals and various lipid peroxides (Landmesser and Harrison 2001; Chandra *et al.*, 2012). Due to the high amount of ROS and the simultaneous reduction of the antioxidant defence system, ROS will alter their molecules to become more toxic radicals. This toxic radical will promote various negative effects on cellular functions such as protein and lipid synthesis disruption, alteration of transcription factors which, in turn, influence various complications, including vascular function (Touyz *et al.*, 2003; Touyz and Schiffrin, 2004) and kidney function and structure (Sachse and Wolf, 2007; Palm and Nordquist, 2011).




Figure 2.1: Oxidative stress is a key factor that leads to hypertension (Santilla *et al.*, 2015). Overproduction of ROS promotes the reduction of NO and at the same time generates high ANG II level. This condition had caused endothelial dysfunction, which lastly promoting hypertension. NO: nitric oxide, ROS: reactive oxygen species, ANG: angiotensin.

Thus, in order to prevent uncontrolled ROS from rising, the redox equilibrium system becomes an important key to maintaining the correct functionality of cellular functions (Schieber and Chandel, 2014; Kurutas, 2016). Redox systems include enzymatic antioxidants (naturally produced by our body, such as catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD) and non-enzymatic antioxidants (externally supplied from other sources, such as vitamins A, C and E, glutathione and several antioxidants present in food). Relatively, enzymatic antioxidants have been considered to be the best known antioxidant defence system for ROS normalisation compared to non-enzymatic antioxidants (Li *et al.*, 2016; Aziz *et al.*, 2019) and have thus far been used as oxidative stress biomarkers in many studies (Sáez *et al.*, 2004; Ahmad *et al.*, 2013).

Various methods have been developed to measure and evaluate oxidative stress in hypertension, including markers for lipid peroxidation, protein oxidation and antioxidant status (Tsiropoulou *et al.*, 2016). The most commonly used assays are lipid peroxidation (such as malondialdehydes (MDA) assay) and antioxidant status (such as total antioxidant capacity (TAC) assay, SOD assay, CAT assay and GPx assay). On the basis of literature, these assays are important to measure in order to determine the biological redox status, at the same time to assess the hypertensive state and progression and the health-enhancing effects of the antioxidant supply in hypertensive people (Marrocco *et al.*, 2017). This is because many studies have shown that hypertensive people usually have higher levels of MDA (Ahmad *et al.*, 2013; Ekeanyanwu *et al.*, 2016) as well as lower levels of SOD activity (Sáez *et al.*, 2004; Ahmad *et al.*, 2013; Baradaran *et al.*, 2014), CAT levels (Sáez *et al.*, 2004; Ahmad *et al.*, 2013) and TAC levels (Onuoha *et al.*, 2013).

2.4 Complications and consequences of hypertension

Hypertension due to oxidative stress is well documented to cause damage to the end organ (Simão *et al.*, 2011). Several important organs, such as the heart, brain, kidneys, blood vessels, and eyes, are the major target organs that are commonly affected during uncontrolled hypertension (Schmeider, 2010; WHO, 2019). Growing evidence has shown that damage to blood vessels and kidneys have had a major impact (Rahimmanesh *et al.*, 2012; Lyle and Taylor., 2019). The total damage to the hypertensive-induced end organ is summarised in Table 2.3.

Table 2.3: End organ damage in arterial hypertension. (Schmeider, 2010).

End organ damage in hypertension	
<p>Vasculopathy</p> <ul style="list-style-type: none"> • Endothelial dysfunction • Remodeling • Generalized atherosclerosis • Arteriosclerotic stenosis • Aortic aneurysm 	<p>Cerebrovascular damage</p> <ul style="list-style-type: none"> • Acute hypertensive encephalopathy • Stroke • Intracerebral haemorrhage • Lacunar infarction • Vascular dementia • Retinopathy
<p>Heart disease</p> <ul style="list-style-type: none"> • Left ventricular hypertrophy • Atrial fibrillation • Coronary microangiopathy • CHD, myocardial infarction • Heart failure 	<p>Nephropathy</p> <ul style="list-style-type: none"> • Albuminuria • Proteinuria • Chronic renal insufficiency • Renal failure

2.4.1 Blood vessel

2.4.1(a) Normal structure of blood vessel

The blood vessel consists of three layers; tunica intima, media and external (Zhao *et al.*, 2015) (Figure 2.2). Tunica intima, the innermost layer, is composed of a single layer of endothelial. The lining is separated from the tunica media by an internal elastic lamina. Whereas, the middle layer; the tunica media mainly consists of a large number of smooth muscle cells, a large number of elastic fibres and connective tissues. The layer of the media is distinguished from the external layer by the external elastic lamina. Apart from that, the outer layer; the outer tunica consists of various elements, including connective tissues, vasa vasorum, fibroblasts and collagen fibres, which help to retain the structure of the vessel. The layer is also composed of nerve ends and perivascular adipose tissue.

In normal vessels, two important components of the blood vessels responsible for maintaining the tone of the vessel (vasoconstriction and vasorelaxation) are vascular smooth muscle cells and endothelial cells. The lumen diameter of the blood vessel is controlled by the smooth muscle cells in the tunica media. It regulates the tone of the vessel by expanding circularly around the lumen (Sandoo *et al.*, 2010). In contrast, endothelial cells found on the surface of the endothelial layer regulate the tone of the blood vessel by releasing vasoconstrictors and vasodilators factors (Vanhoutte *et al.*, 2009; Rajendran *et al.*, 2013) including nitric oxide, prostacyclin, angiotensin II (Ang II), endothelin-1, leukotrienes, and reactive oxygen species (ROS) when endothelial cell alterations occur (Vanhoutte *et al.*, 2009).




Figure 2.2: Blood vessel layers. The layers consist of tunica intima, tunica media, and tunica externa. (Zhao *et al.*, 2015).

Other than that, endothelial cells are also responsible for maintaining the homeostasis process (Durand and Gutterman, 2013; Wang *et al.*, 2015), controlling the flow of blood, regulating the autocrine-paracrine mechanism (Sena *et al.*, 2013), preventing thrombosis (Verhamme and Hoylaerts, 2006; Vanhoutte *et al.*, 2009), regulating the balance between coagulation and fibrinolysis, reducing platelets-leucocytes adhesion (Verhamme and Hoylaerts, 2006; Vanhoutte *et al.*, 2009), and producing inflammatory mediators to prevent inflammation activity (Calvin *et al.*, 2014). Details of the function of endothelial cells are shown in Figure 2.3.




Figure 2.3: Roles of endothelial cell. (Galley, 2004).

2.4.1(b) Alteration of vascular components

A small decrease in the lumen size of the blood vessel due to hypertensive oxidative stress significantly increases the resistance to blood flow. This prolonged blood resistance will alter the structure and function of the vessel (Lyle & Taylor, 2019). The alterations include vascular remodeling, endothelial dysfunction, increased vascular stiffness, and inflammation (Rodrigo *et al.*, 2011; Touyz, 2012; Renna *et al.*, 2013; Montezano *et al.*, 2014). The most common hypertensive complications reported are vascular remodeling and endothelial dysfunction (Savoia *et al.*, 2011; Rahimmanesh *et al.*, 2012; Renna *et al.*, 2013).

Figure 2.4 shows the schematic representation of vascular remodeling in arteries in response to hypertension. Vascular remodeling is indicated by high proliferation and hypertrophy of the smooth muscle cell, migration of monocytes, reduction in elastin levels, high inflammatory cell count, increased apoptosis and increased fibrosis (collagen, fibronectin and extracellular matrix deposition), resulting in thickening of the vascular media and narrowing of the vascular lumen (Intengan and Schiffrin, 2001; Touyz and Schiffrin, 2004; Paneni *et al.*, 2017).

In addition, vascular remodeling can also be found on the endothelial surface of the blood vessel. In normal levels of shear stress (15 - 40 dynes/cm²), endothelial cells line the endothelial layer; normally elongate, align in the direction of blood flow and maintain the barrier function. Too much blood flow, however, will trigger abnormal shear stress. This pressure will cause high friction on the endothelial surface; the endothelial surface will be damaged (Resnick *et al.*, 2003; Yang *et al.*, 2014).




Figure 2.4: The blood vessel underwent vascular remodeling in response to increased resistance to blood flow. Cellular growth of vascular smooth muscle cells (VSMCs), cell migration, rearrangement of VSMCs, extracellular matrix (ECM) deposition, inflammation and endothelial damage (Paneni *et al.*, 2017) are observed.

In addition, damage to the vessel can also be assessed by its functional alterations. In pathological conditions, the function of the endothelial cell will be compromised as it releases a high number of vasoconstrictor factors. This endothelial dysfunction will reduce vascular relaxation and increase vascular contractile activity (Paneni *et al.*, 2017). Many other characteristics of endothelial dysfunction include cell proliferation, fibrosis and adhesion molecules on the wall of the blood vessel (Rahimmanesh *et al.*, 2012).

2.4.2 Renal

2.4.2(a) Normal structure of the kidney

The kidney plays a number of crucial functions. It filters approximately 120 to 150 quarts of blood to produce 1 to 2 quarts of urine, consisting mainly of waste and extra fluid (NIDDK, 2014). A kidney can be divided into three main inner regions (Figure 2.5); renal cortex (outer part of the kidney), renal medulla (inner part of the kidney) and renal pelvis (vessel and nerve of the kidney). There are millions of functional nephronic units or nephron that responsible for filtering the blood, removing waste materials and toxins such as urea, creatinine and uric acid in the form of urine. The nephron itself consists mainly of the renal corpuscle and the renal tubule. There are two main components in the renal corpuscle; the glomerulus and its surrounding Bowman capsule.

The glomerulus is characterised as having a tight capillary ball that supported by a cytoplasmic bundle of actin-like filaments; mesangial cells. These mesangial